BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25572477)

  • 1. Adoptive cell therapy for sarcoma.
    Mata M; Gottschalk S
    Immunotherapy; 2015; 7(1):21-35. PubMed ID: 25572477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away.
    Lee A; Huang P; DeMatteo RP; Pollack SM
    Am Soc Clin Oncol Educ Book; 2016; 35():281-90. PubMed ID: 27249707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy against sarcomas.
    Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
    Huang X; Park H; Greene J; Pao J; Mulvey E; Zhou SX; Albert CM; Moy F; Sachdev D; Yee D; Rader C; Hamby CV; Loeb DM; Cairo MS; Zhou X
    PLoS One; 2015; 10(7):e0133152. PubMed ID: 26173023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for immunotherapy in soft tissue sarcoma.
    Tseng WW; Somaiah N; Engleman EG
    Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell immunotherapy in soft tissue sarcoma.
    Indelicato DJ; Finkelstein SE
    Immunotherapy; 2012 Oct; 4(10):1023-9. PubMed ID: 23148754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolution of T-cell Therapies for Solid Malignancies.
    Fousek K; Ahmed N
    Clin Cancer Res; 2015 Aug; 21(15):3384-92. PubMed ID: 26240290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
    Sebio A; Wilky BA; Keedy VL; Jones RL
    Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From vision to reality: deploying the immune system for treatment of sarcoma.
    Wilky BA; Goldberg JM
    Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
    Rosenberg SA
    Nat Rev Clin Oncol; 2011 Aug; 8(10):577-85. PubMed ID: 21808266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications.
    Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
    Cancer Treat Rev; 2020 Jan; 82():101934. PubMed ID: 31794912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rank aggregation of independent genetic screen results highlights new strategies for adoptive cellular transfer therapy of cancer.
    Vianzon VV; Hanson RM; Garg I; Joseph GJ; Rogers LM
    Front Immunol; 2023; 14():1235131. PubMed ID: 38143765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of sarcomas.
    Goldberg JM
    Curr Opin Oncol; 2013 Jul; 25(4):390-7. PubMed ID: 23736878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
    Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.